Emerging Companies

Aluda: targeting the fundamentals

Five years after its launch, Aluda is pulling back the curtain on its pipeline, leading with a first-in-class anti-VIM therapy for fibrotic indications. CEO Ruihuan Chen co-founded Aluda Pharmaceuticals Inc. in 2015 after 13 years...

Relay’s protein motion platform approaches clinical starting line

With its first program due to enter the clinic this year, Relay will test its hypothesis that characterizing full-length protein targets across a range of conformations leads to better therapeutic candidates than conventional structure-based drug...

Kyverna applies Tregs, CAR Ts to autoimmune diseases with $25M series A, Gilead deal

The team behind Cell Design Labs and its acquirers at Gilead are looking to capitalize on their T cell engineering platform again, bringing it into new indications with the launch of Kyverna. The company is...

Borisy newco aims to offer ‘radically’ cheaper drugs by disrupting biopharma’s traditional model

Alexis Borisy has launched EQRx to disrupt the biopharma world by developing and launching innovative therapies at “radically lower” prices than commercial competitors. With its first drug expected to hit the market in five years,...

NorthSea: Engineering fatty acids for NASH

With its structurally engineered fatty acid platform and a candidate that can hit the three primary mechanisms behind NASH, NorthSea thinks it can succeed in the hepatic and cardiometabolic disease space where so many others...

Empirica: Building a new model for brain cancer

Empirica is developing antibody-based therapies for glioblastoma multiforme using a mouse model built to mimic the biology of recurrent brain cancer, rather than that of primary tumors. Its lead candidate is a CAR T cell...

Rheos: applying immune cell reprogramming to autoimmunity

As immune cell reprogramming is gaining traction in immuno-oncology, Rheos is applying the concept to autoimmune diseases with a platform that can pinpoint metabolic targets in immune cells to control their phenotype and function. The...

Click: personalized digital therapeutics for cognitive, neurobehavioral disorders

Click is developing a pipeline of personalized prescription digital therapeutics that could be used alone or in combination with traditional therapeutics to treat cognitive and neurobehavioral disorders. Launched in 2012, Click Therapeutics Inc. markets a...

Centaurus: inhibiting ceramide synthesis for cardiometabolic disease

Centaurus is aiming for first-in-class small molecules that block the lipotoxicity driving cardiometabolic diseases. Stress stimuli such as inflammation increase production of the structural lipid ceramide, which induces apoptosis, necroptosis and cellular metabolism defects. Centaurus...

Flagship launches Ring with $50M, new gene therapy vectors

Ring Therapeutics, the latest company to emerge from Flagship Pioneering, has a gene therapy platform that it thinks will solve the biggest problems with the modality: immunogenicity, tissue access and genomic integration. With a $50...

Triplet debuts with $59M, therapies for repeat expansion disorders

When new research emerged last year pegging the DNA damage response pathway as a main driver of repeat expansion disorders, rather than the genetic mutations themselves, Atlas Venture co-founded and seeded Triplet with $10 million...

Flagship’s Cellarity maps out network-based drug discovery

Cellarity debuted Tuesday with technology to leverage single cell data to identify compounds that trigger protective changes in molecular networks, without needing to pin their therapeutic effects onto a single target. With $50 million in...

Zentalis debuts with trio of clinical oncology programs, $85M series C

Zentalis emerged from stealth Monday with an untranched and oversubscribed $85 million series C and three internally discovered clinical cancer candidates, with plans to begin pivotal testing by 2021. The C round syndicate includes Matrix...

VaxNewMo: bioconjugating antibacterial vaccines

VaxNewMo is developing a bioengineered platform that could yield inexpensive glyconjugate vaccines that prevent bacterial infections, including those not yet covered by existing vaccines. Traditional chemical glycoconjugation is laborious and expensive, as it typically involves...

Deerfield propels Civetta with $53M series A

Deerfield-backed Civetta Therapeutics LLC is building a platform to systematically identify small molecules targeting β-propeller proteins, a molecular class that has seen little drug development activity despite its ubiquity in the human genome. “There has...